Experimental cancer drug could streamline standard tuberculosis treatment and prevent post-TB lung disease

Experimental cancer drug could streamline standard tuberculosis treatment and prevent post-TB lung disease

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins Medicine investigators report, based on mouse-model research of the lung-damaging disease. Findings from the study, published in Nature Communications, could lead to more effective and less onerous therapies that reduce lung damage in TB survivors. It …